MoonLake Immunotherapeutics(US:MLTX) Prnewswire·2025-10-28 13:51Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake (NASDAQ: MLTX) due to allegations of violations of federal securities laws related to misleading statements about its product SLK compared to BIMZELX [1][3]. Group 1: Allegations Against MoonLake - The complaint alleges that MoonLake and its executives made false and misleading statements regarding the efficacy and clinical benefits of SLK compared to traditional monoclonal antibodies [3]. - Specific claims include that SLK and BIMZELX share the same molecular targets, and that SLK's unique structure does not provide superior clinical benefits or efficacy [3]. - Following the announcement of Phase 3 VELA program results, which showed SLK's failure to demonstrate competitive efficacy, MoonLake's stock price dropped by $55.75 per share, or 89.9%, closing at $6.24 [4]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased MoonLake securities between March 10, 2024, and September 29, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1]. - The deadline for seeking the role of lead plaintiff in the federal securities class action against MoonLake is December 15, 2025 [1]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [5].